.jpg)
Cardiovascular disease remains one of the leading causes of global mortality, and acute myocardial infarction (AMI) represents an urgent clinical challenge. When blood flow to the coronary arteries is interrupted, the heart muscle suffers irreversible damage that, without timely intervention, can lead to cardiac arrest and death. Even survivors face complications such as heart failure or pulmonary edema, with a hospital readmission rate close to 50% during the first year. The therapeutic window for thrombolytic treatment is critical, so accelerating and refining diagnosis is an unresolved medical and technological need.
In this context, artificial intelligence emerges as a strategic ally. Deep learning-based models, combined with specific biomarkers, can identify predictive mortality patterns that escape traditional clinical analysis. The process involves cleaning and preparing large volumes of clinical data, handling missing values, balancing imbalanced datasets using techniques such as SMOTE or ADASYN, and selecting the most relevant variables with wrapper and embedded methods. Then, ensemble architectures—integrating logistic regression, random forest, LightGBM, and bagging SVM—are refined with artificial neural networks to maximize precision, sensitivity, and specificity. This approach allows physicians to have objective and rapid tools to assess the risk of fatal outcomes.
However, transferring these models to clinical practice requires artificial intelligence for companies in the healthcare sector, developed with standards of robustness, scalability, and security. This is where custom software engineering takes center stage. A platform that integrates everything from real-time data capture to result visualization needs a complete technological ecosystem: custom applications that connect with electronic health records, AWS and Azure cloud services to ensure availability and regulatory compliance, and cybersecurity to protect sensitive patient information. Furthermore, the implementation of AI agents capable of continuously monitoring risk factors and alerting healthcare staff can make the difference between life and death.
The value of these systems does not end with prediction. With business intelligence services and tools like Power BI, hospitals can analyze population trends, evaluate treatment effectiveness, and optimize resources. Q2BSTUDIO, as a software development and technology company, offers comprehensive solutions ranging from initial consulting to the deployment of AI models, supporting healthcare institutions in their digital transformation. The combination of deep learning, biomarkers, and customized platforms is redefining preventive cardiology and opening a new era of data-driven medicine.
